Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.83

ProQR Therapeutics (NASDAQ:PRQR) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $8.83.

PRQR has been the subject of several research reports. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $2.33 on Tuesday. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The business has a 50-day simple moving average of $2.41 and a two-hundred day simple moving average of $2.63. The firm has a market cap of $190.31 million, a price-to-earnings ratio of -7.28 and a beta of 0.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $30,000. Invesco Ltd. purchased a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $32,000. Alpine Global Management LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $39,000. Two Sigma Securities LLC purchased a new position in ProQR Therapeutics during the fourth quarter valued at $40,000. Finally, ADAR1 Capital Management LLC purchased a new position in ProQR Therapeutics during the fourth quarter valued at $54,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).